Felbatol and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Felbatol (felbamate), especially for people who are female, 60+ old, have been taking the drug for 2 - 5 years also take Lamictal, and have Angiomyolipoma.

The phase IV clinical study analyzes which people have Weakness when taking Felbatol. It is created by eHealthMe based on reports of 877 people who have side effects when taking Felbatol from the FDA, and is updated regularly.

What is Felbatol?

Felbatol has active ingredients of felbamate. It is often used in epilepsy. eHealthMe is studying from 906 Felbatol users. Check the latest studies of Felbatol.

What is Weakness?

Weakness is found to be associated with 3,641 drugs and 6,611 conditions by eHealthMe. Check the latest studies of Weakness.

On Jul, 10, 2026

877 people reported to have side effects when taking Felbatol.
Among them, 18 people (2.05%) have Weakness.

Among these 18 people:

How long have people been on Felbatol when they have Weakness? *

What is the gender of people who have Weakness when taking Felbatol? *

female: 52.94 %
male: 47.06 %

What is the age of people who have Weakness when taking Felbatol? *

What are other drugs people take besides Felbatol? *

What are other side effects people have besides Weakness? *

Fatigue (feeling of tiredness): 4 people, 22.22%
Dyspnea (difficult or laboured breathing): 4 people, 22.22%
Fever: 3 people, 16.67%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 16.67%
Weight Decreased: 3 people, 16.67%
Chest Pain: 3 people, 16.67%
Chills (felling of cold): 3 people, 16.67%
Dizziness: 3 people, 16.67%
Depression: 3 people, 16.67%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 2 people, 11.11%

What are the existing conditions these people have? *

Tuberous Sclerosis (a rare genetic disease that causes benign tumours to grow in the brain and other organs): 2 people, 11.11%
Astrocytoma, Low Grade (low grade tumour of the brain that originate in a particular kind of glial-cells): 2 people, 11.11%
Angiomyolipoma (most common benign tumour of the kidney): 2 people, 11.11%
Pain: 1 person, 5.56%
Migraine (headache): 1 person, 5.56%
Lennox-Gastaut Syndrome (epilepsy characterized by frequent seizures and different seizure types): 1 person, 5.56%
Ill-Defined Disorder: 1 person, 5.56%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.56%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 5.56%
Complex Partial Seizures (epileptic seizure): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Felbatol and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Felbatol:

Felbatol (906 reports)

Weakness treatments and more:

Weakness (586,876 reports)

Browse all side effects of Felbatol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,641 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,611 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on felbamate (the active ingredients of Felbatol) and Felbatol (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.